Nymox Pharmaceutical Company Profile (NASDAQ:NYMX)

About Nymox Pharmaceutical

Nymox Pharmaceutical logoNymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also has a patent portfolio covering its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex conducts research and development, and manufacturing for NicAlert and TobacAlert.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NYMX
  • CUSIP:
Key Metrics:
  • Previous Close: $3.54
  • 50 Day Moving Average: $3.21
  • 200 Day Moving Average: $3.14
  • 52-Week Range: $1.62 - $5.79
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.19
  • P/E Growth: 0.00
  • Market Cap: $169.00M
  • Outstanding Shares: 47,875,000
  • Beta: 0.77
Profitability:
  • Net Margins: -4,510.97%
  • Return on Assets: -1,522.75%
Debt:
  • Debt-to-Equity Ratio: -0.63%
  • Current Ratio: 0.92%
  • Quick Ratio: 0.91%
Additional Links:
Companies Related to Nymox Pharmaceutical:

Analyst Ratings

Consensus Ratings for Nymox Pharmaceutical (NASDAQ:NYMX) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Nymox Pharmaceutical (NASDAQ:NYMX)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Nymox Pharmaceutical (NASDAQ:NYMX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2014Q314($0.02)ViewN/AView Earnings Details
5/15/2014Q114$0.07$0.18 million$0.08 millionViewN/AView Earnings Details
3/14/2014($0.06)($0.04)ViewN/AView Earnings Details
11/13/2013Q3($0.03)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.05)($0.03)$0.78 million$0.18 millionViewN/AView Earnings Details
11/14/2012Q312($0.06)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Nymox Pharmaceutical (NASDAQ:NYMX)
Current Year EPS Consensus Estimate: $-0.20 EPS
Next Year EPS Consensus Estimate: $-0.57 EPS

Dividends

Dividend History for Nymox Pharmaceutical (NASDAQ:NYMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Nymox Pharmaceutical (NASDAQ:NYMX)
Insider Ownership Percentage: 54.00%
Institutional Ownership Percentage: 1.76%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/10/2016James George RobinsonDirectorBuy500$2.47$1,235.00View SEC Filing  
8/4/2016James George RobinsonDirectorBuy7,000$3.41$23,870.00View SEC Filing  
7/29/2016James George RobinsonDirectorBuy22,500$3.86$86,850.00View SEC Filing  
7/20/2016James George RobinsonDirectorBuy10,000$3.33$33,300.00View SEC Filing  
7/7/2016James George RobinsonDirectorBuy20,000$3.28$65,600.00View SEC Filing  
6/29/2016James George RobinsonDirectorBuy17,500$3.53$61,775.00View SEC Filing  
6/24/2016James George RobinsonDirectorBuy22,500$2.97$66,825.00View SEC Filing  
5/13/2016James George RobinsonDirectorBuy28,010$2.31$64,703.10View SEC Filing  
5/3/2016James George RobinsonDirectorBuy6,990$2.36$16,496.40View SEC Filing  
4/29/2016James George RobinsonDirectorBuy15,000$2.27$34,050.00View SEC Filing  
4/15/2016James George RobinsonDirectorBuy39,500$2.39$94,405.00View SEC Filing  
4/1/2016James George RobinsonDirectorBuy20,500$2.40$49,200.00View SEC Filing  
3/24/2016James George RobinsonDirectorBuy40,000$2.29$91,600.00View SEC Filing  
1/12/2016James George RobinsonDirectorBuy20,000$2.44$48,800.00View SEC Filing  
1/8/2016James George RobinsonDirectorBuy95,000$2.90$275,500.00View SEC Filing  
12/30/2015James George RobinsonDirectorBuy5,000$3.38$16,900.00View SEC Filing  
12/29/2015James George RobinsonDirectorBuy14,000$3.55$49,700.00View SEC Filing  
12/28/2015James George RobinsonDirectorBuy6,000$3.79$22,740.00View SEC Filing  
12/23/2015James George RobinsonDirectorBuy29,854$3.54$105,683.16View SEC Filing  
12/18/2015James George RobinsonDirectorBuy63,334$3.56$225,469.04View SEC Filing  
12/11/2015James George RobinsonDirectorBuy46,812$3.51$164,310.12View SEC Filing  
12/4/2015James George RobinsonDirectorBuy110,000$3.44$378,400.00View SEC Filing  
9/3/2015James George RobinsonDirectorBuy100,000$2.25$225,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Nymox Pharmaceutical (NASDAQ:NYMX)
DateHeadline
News IconStock Tracker: Trend Analysis on Nymox Pharmaceutical Corp (NYMX) - Rives Journal (NASDAQ:NYMX)
rivesjournal.com - February 23 at 12:07 AM
News IconTrading Views: Checking the Numbers for Nymox Pharmaceutical Corporation (NYMX) - Benton Bulletin (NASDAQ:NYMX)
bentonbulletin.com - February 18 at 6:08 PM
News IconA Favorite Among Institutions: Nymox Pharmaceutical Corporation ... - Rockville Register (NASDAQ:NYMX)
rockvilleregister.com - February 15 at 3:20 AM
News IconShares Holding Above Moving Averages: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Winfield Review (NASDAQ:NYMX)
winfieldreview.com - February 15 at 3:20 AM
News IconInvestor Technical Review for Nymox Pharmaceutical Corporation (NYMX) - Baldwin Journal (NASDAQ:NYMX)
baldwinjournal.com - February 14 at 1:13 AM
News IconInvestor Focus on Shares of Nymox Pharmaceutical Corporation (NYMX) - Sherwood Daily (NASDAQ:NYMX)
sherwooddaily.com - February 10 at 7:55 PM
News IconNymox Pharmaceutical Corporation (NASDAQ:NYMX) Institutional Ownership stands at 1.7 - The Newburgh Press (NASDAQ:NYMX)
newburghpress.com - February 9 at 5:57 AM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Nelson Research (NASDAQ:NYMX)
nelsonobserver.com - February 1 at 6:16 AM
News IconOncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) Features an Intersection of Promising Dynamics - Journal Transcript (NASDAQ:NYMX)
www.journaltranscript.com - January 31 at 7:56 PM
News IconTrading Lines in Focus for Nymox Pharmaceutical Corporation ... - Sherwood Daily (NASDAQ:NYMX)
sherwooddaily.com - January 31 at 7:56 PM
News IconStock Vacillating as Volatility Hits a High Point For Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Wall Street Beacon (NASDAQ:NYMX)
wsbeacon.com - January 31 at 7:56 PM
News IconSmall Cap Concentration on Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Prospect Journal (NASDAQ:NYMX)
prospectjournal.com - January 31 at 7:56 PM
reuters.com logoProfile: Nymox Pharmaceutical Corp (NYMX.OQ) (NASDAQ:NYMX)
www.reuters.com - January 28 at 7:04 PM
News IconEquity Research Analysts Peer Into Their Crystal Ball For Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Aiken Advocate (NASDAQ:NYMX)
aikenadvocate.com - January 28 at 5:25 AM
News IconQuick Review on Trend Indicator Levels: Nymox Pharmaceutical Corporation (NYMX) - Sherwood Daily (NASDAQ:NYMX)
sherwooddaily.com - January 28 at 5:25 AM
News IconMr. Market is Discovering OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) - Journal Transcript (NASDAQ:NYMX)
www.journaltranscript.com - January 27 at 4:54 AM
News IconOncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) Provides Positive Update on ProscaVax Data - WallStreetPR (NASDAQ:NYMX)
wallstreetpr.com - January 27 at 4:54 AM
News IconWall Street Holds Inauguration Gains, How Did This Stock Fare: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Wall Street Beacon (NASDAQ:NYMX)
wsbeacon.com - January 23 at 9:42 AM
News IconTrump Sworn In as S&P Declined, How Did this Stock Perform This Week: Nymox Pharmaceutical Corporation ... - Aiken Advocate (NASDAQ:NYMX)
aikenadvocate.com - January 21 at 6:45 PM
News IconOncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) Potential Breakthrough Study Could Send Stock Prices Surging - Journal Transcript (NASDAQ:NYMX)
www.journaltranscript.com - January 20 at 4:33 AM
News IconOncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) Presents Interesting Picture as a Bite-Size Buyout Candidate (NASDAQ:NYMX)
wallstreetpr.com - January 17 at 11:23 AM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Wall Street Beacon (NASDAQ:NYMX)
wsbeacon.com - January 15 at 7:01 AM
News IconBounding Shares, What's Next for Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Prospect Journal (NASDAQ:NYMX)
prospectjournal.com - January 13 at 5:40 AM
News IconZeroing in on Company Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Prospect Journal (NASDAQ:NYMX)
prospectjournal.com - January 11 at 6:01 AM
News IconCan This Stock Grab Upward Traction: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Prospect Journal (NASDAQ:NYMX)
prospectjournal.com - January 10 at 8:48 AM
News IconNymox Pharmaceutical Corp NYMX Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:NYMX)
www.bioportfolio.com - January 7 at 11:12 PM
News IconDelving into Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Prospect Journal (NASDAQ:NYMX)
prospectjournal.com - January 5 at 5:50 AM
News IconAre Cagey Traders Interested in These Shares: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Prospect Journal (NASDAQ:NYMX)
prospectjournal.com - December 30 at 8:44 AM
News IconIs Now the Time to Capitalize on Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Prospect Journal (NASDAQ:NYMX)
prospectjournal.com - December 29 at 9:22 AM
News IconDiagnostic Substances Stocks On Investors' Radar - Palatin Technologies, AMAG Pharma, Nymox Pharma, And IDEXX ... - Laboratory Network (NASDAQ:NYMX)
www.laboratorynetwork.com - December 28 at 9:58 AM
News IconUnder the Microscope We Place Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Prospect Journal (NASDAQ:NYMX)
prospectjournal.com - December 28 at 9:58 AM
investorplace.com logoHottest Manufacturing Stocks Now – FOLD AQXP NLNK ACHN - Investorplace.com (NASDAQ:NYMX)
investorplace.com - December 27 at 9:57 AM
News IconCan This Stock Pick Up Any Momentum: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Prospect Journal (NASDAQ:NYMX)
prospectjournal.com - December 22 at 8:06 AM
News IconShares Aiming Higher Pre-Bell: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Prospect Journal (NASDAQ:NYMX)
prospectjournal.com - December 20 at 1:08 PM
News IconBargain Hunters Should Take a Look at Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Prospect Journal (NASDAQ:NYMX)
prospectjournal.com - December 20 at 1:08 PM
4-traders.com logoIDEXX Laboratories : Diagnostic Substances Stocks on Investors' Radar -- Palatin Technologies, AMAG Pharma, Nymox Pharma, and IDEXX Laboratories (NASDAQ:NYMX)
www.4-traders.com - December 19 at 9:12 AM
News IconTop Stock With Upside & Growth Potential: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Prospect Journal (NASDAQ:NYMX)
prospectjournal.com - December 13 at 9:10 AM
News IconMarket Focus: Checking Indicators on Shares of Nymox Pharmaceutical Corporation (NYMX) - Yankee Analysts (NASDAQ:NYMX)
yankeeanalysts.com - December 3 at 10:53 AM
News IconInvestor Arena: Keeping an Eye on Nymox Pharmaceutical Corporation (NYMX) - Yankee Analysts (NASDAQ:NYMX)
yankeeanalysts.com - December 2 at 12:27 PM
fxpips.com logoActive Stocks Rising Up Now - SGOC, ISIG, WGBS, COGT, VBLT, THO, NYMX - FxPips.com (NASDAQ:NYMX)
www.fxpips.com - December 1 at 9:05 AM
investingnews.com logoNymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies (NASDAQ:NYMX)
investingnews.com - November 30 at 7:07 PM
us.rd.yahoo.com logo9:45 am Nymox Pharma reports additional 'positive' results from fexapotide BPH phase 3 studies showing 'significant early response' and first-line efficacy (NASDAQ:NYMX)
us.rd.yahoo.com - November 30 at 7:07 PM
streetinsider.com logoNymox Pharma (NYMX) Announces Additional Positive Data from Fexapotide Phase 3 in BPH - StreetInsider.com (NASDAQ:NYMX)
www.streetinsider.com - November 29 at 2:25 PM
News IconTrading Activity in Focus for Nymox Pharmaceutical Corporation (NYMX) - Yankee Analysts (NASDAQ:NYMX)
yankeeanalysts.com - November 29 at 2:25 PM
finance.yahoo.com logoNymox Reports Additional Positive Results From Completed Fexapotide BPH Phase 3 Studies Showing Significant Early Response and First-Line Efficacy (NASDAQ:NYMX)
finance.yahoo.com - November 29 at 2:25 PM
News IconTrading Sheet: Tracking Technicals for Nymox Pharmaceutical Corporation (NYMX) - Yankee Analysts (NASDAQ:NYMX)
yankeeanalysts.com - November 22 at 6:44 PM
News IconWhat are the Levels Indicating for This Stock: Nymox Pharmaceutical Corporation (NYMX) - Yankee Analysts (NASDAQ:NYMX)
yankeeanalysts.com - November 21 at 7:04 PM
News IconStock Review: ADX, MA, RSI Numbers in View for Nymox Pharmaceutical Corporation (NYMX) - MicroCap Wired (NASDAQ:NYMX)
www.microcapwired.com - November 21 at 11:53 AM
News IconTracking Technical Levels on Shares of Nymox Pharmaceutical Corporation (NYMX) - MicroCap Wired (NASDAQ:NYMX)
www.microcapwired.com - November 18 at 9:47 AM
News IconStock Alert - Nymox Pharmaceutical Corporation's (NYMX) - Hot Stocks Point (NASDAQ:NYMX)
www.hotstockspoint.com - November 18 at 9:47 AM

Social

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

How do I buy Nymox Pharmaceutical stock?

Shares of Nymox Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Nymox Pharmaceutical stock cost?

One share of Nymox Pharmaceutical stock can currently be purchased for approximately $3.53.

Nymox Pharmaceutical (NASDAQ:NYMX) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Earnings History Chart

Earnings by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Dividend History Chart

Dividend Payments by Quarter for Nymox Pharmaceutical (NASDAQ:NYMX)

Last Updated on 2/24/2017 by MarketBeat.com Staff